First clinical studies on mabuterol. A summarizing report.
In a dose finding study, a total of 245 asthmatic patients were given a single dose of 30, 40, 50, 60, 70 and 80 micrograms of dl-1-(4-amino-3-chloro-5-trifluoromethyl-phenyl)-2-tert.-butylamino-etha nol hydrochloride (mabuterol). From the results, 50 micrograms of mabuterol proved to be the optimal single dose in terms of effectiveness and tolerability. In a multicenter comparative study, asthmatic patients were treated with 50 or 75 micrograms of mabuterol twice a day for 6 weeks. From the results, 50 micrograms of mabuterol twice a day proved to be optimally effective and tolerable.
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000328:Adult; D001249:Asthma / Q000188:drug therapy* / Q000503:physiopathology; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002319:Cardiovascular System / Q000187:drug effects; D002908:Chronic Disease; D002976:Clenbuterol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D004983:Ethanolamines / Q000627:therapeutic use*; D006801:Humans; D011897:Random Allocation; D012129:Respiratory Function Tests
D000319:Adrenergic beta-Antagonists; D001993:Bronchodilator Agents; D004983:Ethanolamines; C044573:mabuterol; D002976:Clenbuterol